Resuscitation with a blood substitute abrogates pathologic postinjury neutrophil cytotoxic function.
BACKGROUND
Resuscitation with oxygen-carrying fluids is critically important in the patient with hemorrhagic shock caused by trauma. However, it is clear that a number of biologic mediators present in stored blood (packed red blood cells [PRBCs]) have the potential to exacerbate early postinjury hyperinflammation and multiple organ failure through priming of circulating neutrophils (PMNs). PolyHeme (Northfield Laboratories, Evanston, IL), a hemoglobin-based substitute that is free of priming agents, provides an alternative. We hypothesized that PMN priming would be attenuated in patients resuscitated with PolyHeme in lieu of stored blood.


METHODS
Injured patients requiring urgent transfusion were given either PolyHeme (up to 20 units) or PRBCs. Early postinjury PMN priming was measured via beta-2 integrin expression, superoxide production, and elastase release.


RESULTS
Treatment groups were comparable with respect to extent of injury and early physiologic compromise. PMNs from patients resuscitated with PRBCs showed priming in the early postinjury period by all three measures. No such priming was evident in patients resuscitated with PolyHeme.


CONCLUSIONS
The use of a blood substitute in the early postinjury period avoids PMN priming and may thereby provide an avenue to decrease the incidence or severity of postinjury multiple organ failure.
Johnson
J L
JL
Department of Surgery, Denver Health Medical Center, Denver, Colorado, USA.
Moore
E E
EE
Offner
P J
PJ
Partrick
D A
DA
Tamura
D Y
DY
Zallen
G
G
Silliman
C C
CC
D001794:Blood Pressure; D001802:Blood Substitutes / Q000627:therapeutic use*; D018821:CD18 Antigens / Q000097:blood; D003602:Cytotoxicity, Immunologic / Q000276:immunology*; D006454:Hemoglobins / Q000276:immunology* / Q000627:therapeutic use*; D006801:Humans; D007249:Inflammation; D015601:Injury Severity Score; D009102:Multiple Organ Failure / Q000209:etiology; D009104:Multiple Trauma / Q000145:classification / Q000150:complications* / Q000276:immunology*; D009504:Neutrophils / Q000276:immunology*; D010196:Pancreatic Elastase / Q000097:blood; D011446:Prospective Studies; D011732:Pyridoxal Phosphate / Q000031:analogs & derivatives* / Q000276:immunology* / Q000627:therapeutic use*; D012151:Resuscitation / Q000379:methods*; D012771:Shock, Hemorrhagic / Q000209:etiology* / Q000378:metabolism / Q000628:therapy*; D013481:Superoxides / Q000097:blood; D016896:Treatment Outcome
D001802:Blood Substitutes; D018821:CD18 Antigens; D006454:Hemoglobins; C030939:polyhemoglobin-pyridoxal-5-phosphate; D013481:Superoxides; D011732:Pyridoxal Phosphate; D010196:Pancreatic Elastase